Impact of Age on Gender Difference in Long-term Outcome of Patients With Acute Myocardial Infarction (from J-MINUET)

Am J Cardiol. 2021 Mar 1:142:5-13. doi: 10.1016/j.amjcard.2020.11.042. Epub 2020 Dec 3.

Abstract

Although gender difference in long-term outcomes after acute myocardial infarction have been shown previously, impact of age on gender difference is still controversial. This study focused on the association between age and gender difference in long-term outcome. We analyzed data from 3,283 consecutive patients who were included in a prospective, nationwide, multicenter registry (Japan Registry of Acute Myocardial Infarction Diagnosed by Universal Definition) from 2012 to 2014. The primary end point was the major adverse cardiovascular event (MACE), which was defined as a composite of death, myocardial infarction, stroke, heart failure, and revascularization for unstable angina during 3 years. Patients were divided into 4 strata according to age: those with age <65 years (group 1: n = 1161), 65 to 74 years (group 2: n = 954), 75 to 84 years (group 3: n = 866) and 84< years (group 4: n = 302). Although the crude incidence of 3-year MACE was significantly higher in women than men (36.4% vs. 28.5%, p <0.001), there was not significant gender difference in each group (group 1, 19.6% vs 19.0%, p = 0.74; group 2, 33.1% vs 28.3%, p = 0.25; group 3, 38.9% vs 39.6%, p = 0.54; and group 4, 54.0% vs 56.8%, p = 0.24). In conclusion, although women had higher crude incidence of 3-year MACE than men, there was no gender difference in each group.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Angina, Unstable / epidemiology
  • Angina, Unstable / surgery
  • Atrial Fibrillation / epidemiology
  • Coronary Angiography
  • Female
  • Guideline Adherence / statistics & numerical data
  • Heart Failure / epidemiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Japan / epidemiology
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Mortality
  • Myocardial Infarction / epidemiology
  • Myocardial Infarction / therapy*
  • Myocardial Revascularization / statistics & numerical data
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Practice Guidelines as Topic
  • Prognosis
  • Recurrence
  • Registries
  • Renal Insufficiency, Chronic / epidemiology
  • Sex Factors
  • Stroke / epidemiology
  • Time-to-Treatment / statistics & numerical data*

Substances

  • Adrenergic beta-Antagonists
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors